Recent Updates
Recently added Catalysts

Modified Constraint-induced movement therapy

Phase 1

Hemiparesis | Unknown | Neurology |Verona Pharma plc Sponsored ADR|Last Updated: May 15, 2007

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment10
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00473447A Modified Constraint-Induced Movement Therapy Program in Rehabilitation of Arm Paresis in Children With Cerebral PalsyPHASE1 COMPLETED 10Jan 1, 2004Apr 1, 2006May 15, 2007 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Arm Use Test
Four months for each patient
Secondary Endpoints
Arm Function Test
Four months for each patient
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelCROSSOVER
PurposeTREATMENT
Interventions
NameTypeDescription
Modified Constraint-induced movement therapyBEHAVIORAL -
Unlock Study Design Details
Eligibility Criteria
Age Range1 Year — 10 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * presence of mild-moderate arm paresis (after cerebral palsy) enabling to * reach and grasp a pellet * age between 1-10 years * active participation during proposed activities * parents consent for participation - Exclusion Criteria: * presence of severe behaviour disturbance...

Unlock Eligibility Criteria